Pembrolizumab in soft-tissue sarcomas with ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Auteur(s) :
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Institut Gustave Roussy [IGR]
Université de Bordeaux [UB]
Bessede, A. [Auteur]
Pulido, M. [Auteur]
Institut Bergonié [Bordeaux]
Bompas, E. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Piperno-Neumann, S. [Auteur]
Institut Curie [Paris]
Chevreau, C. [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bertucci, F. [Auteur]
Institut Paoli-Calmettes [IPC]
Toulmonde, M. [Auteur]
Institut Bergonié [Bordeaux]
Bellera, C. [Auteur]
Institut Bergonié [Bordeaux]
Guegan, J. P. [Auteur]
Rey, C. [Auteur]
Sautès-Fridman, C. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Bougoüin, A. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Cantarel, C. [Auteur]
Institut Bergonié [Bordeaux]
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
Kind, M. [Auteur]
Institut Bergonié [Bordeaux]
Spalato, M. [Auteur]
Institut Bergonié [Bordeaux]
Dadone-Montaudie, B. [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Le Loarer, F. [Auteur]
Institut Bergonié [Bordeaux]
Université de Bordeaux [UB]
Blay, J. Y. [Auteur]
Department of Medical Oncology [Lyon]
Fridman, W. H. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Kind, M. [Auteur]
Institut Bergonié [Bordeaux]
Institut Gustave Roussy [IGR]
Université de Bordeaux [UB]
Bessede, A. [Auteur]
Pulido, M. [Auteur]
Institut Bergonié [Bordeaux]
Bompas, E. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Piperno-Neumann, S. [Auteur]
Institut Curie [Paris]
Chevreau, C. [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bertucci, F. [Auteur]
Institut Paoli-Calmettes [IPC]
Toulmonde, M. [Auteur]
Institut Bergonié [Bordeaux]
Bellera, C. [Auteur]
Institut Bergonié [Bordeaux]
Guegan, J. P. [Auteur]
Rey, C. [Auteur]
Sautès-Fridman, C. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Bougoüin, A. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Cantarel, C. [Auteur]
Institut Bergonié [Bordeaux]
BoRdeaux Institute in onCology [Inserm U1312 - BRIC]
Kind, M. [Auteur]
Institut Bergonié [Bordeaux]
Spalato, M. [Auteur]
Institut Bergonié [Bordeaux]
Dadone-Montaudie, B. [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Le Loarer, F. [Auteur]
Institut Bergonié [Bordeaux]
Université de Bordeaux [UB]
Blay, J. Y. [Auteur]
Department of Medical Oncology [Lyon]
Fridman, W. H. [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Ligue Nationale Contre le Cancer - Paris
Kind, M. [Auteur]
Titre de la revue :
Nature Medicine
Nom court de la revue :
Nat Med
Date de publication :
2022-05-29
ISSN :
1546-170X
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated ...
Lire la suite >Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in these patients. PEMBROSARC is a multicohort phase 2 study of pembrolizumab combined with low-dose cyclophosphamide in patients with advanced STS (NCT02406781). The primary endpoint was the 6-month non-progression rate (NPR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety. The 6-month NPR and ORRs for cohorts in this trial enrolling all comers were previously reported; here, we report the results of a cohort enrolling patients selected based on the presence of TLSs (n = 30). The 6-month NPR was 40% (95% confidence interval (CI), 22.7–59.4), so the primary endpoint was met. The ORR was 30% (95% CI, 14.7–49.4). In comparison, the 6-month NPR and ORR were 4.9% (95% CI, 0.6–16.5) and 2.4% (95% CI, 0.1–12.9), respectively, in the all-comer cohorts. The most frequent toxicities were grade 1 or 2 fatigue, nausea, dysthyroidism, diarrhea and anemia. Exploratory analyses revealed that the abundance of intratumoral plasma cells (PCs) was significantly associated with improved outcome. These results suggest that TLS presence in advanced STS is a potential predictive biomarker to improve patients’ selection for pembrolizumab treatment.Lire moins >
Lire la suite >Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in these patients. PEMBROSARC is a multicohort phase 2 study of pembrolizumab combined with low-dose cyclophosphamide in patients with advanced STS (NCT02406781). The primary endpoint was the 6-month non-progression rate (NPR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety. The 6-month NPR and ORRs for cohorts in this trial enrolling all comers were previously reported; here, we report the results of a cohort enrolling patients selected based on the presence of TLSs (n = 30). The 6-month NPR was 40% (95% confidence interval (CI), 22.7–59.4), so the primary endpoint was met. The ORR was 30% (95% CI, 14.7–49.4). In comparison, the 6-month NPR and ORR were 4.9% (95% CI, 0.6–16.5) and 2.4% (95% CI, 0.1–12.9), respectively, in the all-comer cohorts. The most frequent toxicities were grade 1 or 2 fatigue, nausea, dysthyroidism, diarrhea and anemia. Exploratory analyses revealed that the abundance of intratumoral plasma cells (PCs) was significantly associated with improved outcome. These results suggest that TLS presence in advanced STS is a potential predictive biomarker to improve patients’ selection for pembrolizumab treatment.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Date de dépôt :
2023-11-15T04:03:43Z
2024-01-18T09:05:26Z
2024-01-18T09:05:26Z